Q-omics provides the consensus-scored PSMB7 profile across patient tissues and cancer cell-line models. PSMB7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PSMB7 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, PSMB7 protein abundance shows 27,324 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where PSMB7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMB7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMB7 survival associations across molecular data types. PSMB7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMB7 RNA expression–survival associations across cancer types. High PSMB7 expression shows unfavorable associations in ACC, LUAD, UCS, HNSC and BLCA, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PSMB7 RNA expression.
This table summarizes PSMB7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PSMB7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMB7 shows higher tumor expression in HNSC, COAD, KIRC, STAD, LUSC and LIHC. The HNSC box plot shows higher PSMB7 RNA expression in tumor versus normal tissue (log2 FC = +1.156, t-test p < 0.001).
This table shows molecular features associated with PSMB7 in patient tissues and cancer cell lines. In patient samples, PSMB7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PSMB7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and PANCREAS.
